What Happened?

Millions of American women navigate menopause with little medical support, and for the first time, Congress put that problem directly on the record. The Senate Special Committee on Aging held its first hearing focused on menopause on Sept. 16, examining gaps in research, physician training, and patient care.

Sen. Rick Scott (R-FL) chaired the session. Sen. Kirsten Gillibrand (D-NY) served as the top Democrat on the committee. Four witnesses testified, representing public health, medicine, women's advocacy, and the federal office that oversees women's health at the Department of Health and Human Services (HHS).

Why Does it Matter to Me?

If you or someone you know is among the roughly half of the population who will go through menopause, finding a doctor who knows how to help is already hard. Gillibrand said the average wait to see an OB-GYN runs more than one month, with even longer waits in rural areas.

Witness Jean Wactawski-Wende of the University at Buffalo told the committee that research on women's health, especially for older women, has been underfunded for years. Without more studies on how hormonal changes across a woman's lifespan affect long-term health, doctors lack the evidence they need to treat patients well.

Both Sides, Now

Gillibrand said she wants greater federal investment in menopause research and changes to address what she called providers' lack of preparedness. She and Scott announced a joint, bipartisan request to the Government Accountability Office (GAO), the nonpartisan federal watchdog, to examine federal menopause activities, physician training, and gaps in research and care.

According to Ms. magazine, the administration proposed cutting the National Institutes of Health budget by roughly 43 percent. The Center for American Progress reported the proposed fiscal year 2026 HHS budget would cut that department by more than 26 percent. On the other side of the ledger, the Food and Drug Administration announced in November 2025 that it would remove broad warning labels from estrogen-containing hormone therapy products, a move some advocates welcomed as removing a barrier to treatment. HHS also said it would restore some funding for the Women's Health Initiative, a long-running federal study on women's health.

The hearing record lists no vote, motion, or other committee action taken on Sept. 16.

What Happens Next?

The immediate next step is the GAO review that Scott and Gillibrand requested together. That review would look at what the federal government currently does on menopause, how well doctors are trained, and where the biggest gaps in research and care exist. No timeline for the GAO's findings has been announced.

Beyond that, no bill has been introduced, no vote is scheduled, and no markup is planned. For anything to change in federal policy, Congress would need to act through legislation or the annual budget process, both of which remain open questions.

---

This article was generated by AI pulling from data. Each article is edited by an editor for accuracy and clarity.

---

Spot something wrong? Report an issue with this article